[The revolution of AI in drug development].

Journal: Medecine sciences : M/S
Published Date:

Abstract

Artificial intelligence and machine learning enable the construction of predictive models, which are currently used to assist in decision-making throughout the process of drug discovery and development. These computational models can be used to represent the heterogeneity of a disease, identify therapeutic targets, design and optimize drug candidates, and evaluate the efficacy of these drugs on virtual patients or digital twins. By combining detailed patient characteristics with the prediction of potential drug-candidate properties, artificial intelligence promotes the emergence of a "computational" precision medicine, allowing for more personalized treatments, better tailored to patient specificities with the aid of such predictive models. Based on such new capabilities, a mixed reality approach to the development of new drugs is being adopted by the pharmaceutical industry, which integrates the outputs of predictive virtual models with real-world empirical studies.

Authors

  • Philippe Moingeon
    Servier, Research and Development, 50 rue Carnot, 92284 Suresnes Cedex, France. Electronic address: philippe.moingeon@servier.com.
  • Christiane Garbay
    Académie nationale de pharmacie, Paris, France.
  • Muriel Dahan
    Académie nationale de pharmacie, Paris, France.
  • Irène Fermont
    Académie nationale de pharmacie, Paris, France.
  • Ali Benmakhlouf
    Académie nationale de pharmacie, Paris, France.
  • Alain Gouyette
    Académie nationale de pharmacie, Paris, France.
  • Pierre Poitou
    Académie nationale de pharmacie, Paris, France.
  • Alain Saint-Pierre
    Académie nationale de pharmacie, Paris, France.